Literature DB >> 15786828

Thrombocytopenia and anaphylaxis secondary to heparin in a hemodialysis patient.

M A Tejedor Alonso1, K López Revuelta, M J García Bueno, M L Casas Losada, A Rosado Ingelmo, E Gruss Vergara, C Vila Albelda, M Moro Moro.   

Abstract

AIMS: We describe a rare case of anaphylaxis and thrombocytopenia whose cause was heparin used during hemodialysis sessions. CASE REPORT: A 77-year-old woman suffered five consecutive episodes of vomiting, tachypnea, wheezing or rales, immediately after initiating hemodialysis. In the first of these episodes, arterial pressure was undetectable. In all of the episodes there was evidence of the presence of hypoxia (always below 60 mmHg) and thrombocytopenia (always below l00,000/microl,, with partial platelets recovery among episodes. The episodes started immediately after hemodialysis sessions and heparin infusion; either sodium heparin or enoxaparin was used. Utilization of different filters was not able to stop the episodes. These were stopped when a switch from heparin to hirudin was tested. Tryptase levels, as a marker of mast cells activation and anaphylaxis, were not increased in two of the episodes which were assessed. IgG antibodies against heparin-PF4 complex was detected at high levels. DISCUSSION: A diagnosis of concomitant anaphylaxis and thrombocytopenia caused by sodium heparin and a low-molecular weight heparin (enoxaparin) were assumed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15786828     DOI: 10.5414/cnp63236

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  3 in total

1.  84-year-old woman with hemodialysis-associated shortness of breath.

Authors:  Suraj Kapa; Qi Qian
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

Review 2.  [Thrombocytopathy and blood complications in uremia].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

3.  A case series: Association of anaphylaxis with a significant decrease in platelet levels and possible secondary risk of thrombosis.

Authors:  Brian P Peppers; Anant Vatsayan; Jignesh Dalal; Tracey Bonfield; Haig Tcheurekdjian; Robert Hostoffer
Journal:  Immun Inflamm Dis       Date:  2018-04-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.